• Oral anti-TNF meets efficacy endpoints in mild-to-moderate UC trial

    5 monthes ago - By Healio

    Protalix BioTherapeutics announced that its novel, oral anti-TNF therapy, OPRX-106, met key efficacy endpoints in a phase 2 trial of patients with mild-to-moderate ulcerative colitis.
    “The data is very encouraging, suggesting that OPRX-106 could potentially address a large unmet medical need in the treatment of ulcerative colitis. OPRX-106 is delivered orally and is biologically active in the gut without triggering the formation of anti-drug antibodies. OPRX-106 has the potential to address the partial loss of response seen in anti-TNF alpha treatment, which is driven by the high
    Read more ...